Eli Lilly And Company ( (LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is a global pharmaceutical firm known for its innovative research and development in the healthcare sector, focusing on treatments for diabetes, cancer, and other significant health challenges. In its latest earnings report, Eli Lilly announced a robust 54% increase in revenue for the third quarter of 2025, reaching $17.60 billion, primarily driven by the strong performance of its key products, Mounjaro and Zepbound. The company’s earnings per share (EPS) also saw a significant rise, with reported EPS increasing to $6.21 and non-GAAP EPS reaching $7.02.
Key financial highlights include a substantial increase in net income, which rose to $5.58 billion from $970.3 million in the previous year. The company also reported progress in its research and development pipeline, with positive results from four Phase 3 trials of orforglipron, and the U.S. FDA approval of Inluriyo for advanced breast cancer treatment. Additionally, Eli Lilly announced plans to expand its manufacturing capabilities with new facilities in Virginia and Texas, and an expansion in Puerto Rico.
The company’s strategic focus on expanding its product portfolio and manufacturing capacity is evident from its recent investments and regulatory achievements. Eli Lilly’s strong performance is further underscored by its increased full-year revenue guidance, now projected to be between $63.0 billion and $63.5 billion, with EPS guidance also raised.
Looking ahead, Eli Lilly remains committed to advancing its pipeline and expanding its market presence. The company is poised for continued growth, driven by its strategic investments and ongoing innovation in the pharmaceutical industry.